Basics |
Amylyx Pharmaceuticals, Inc.
|
IPO Date: |
January 7, 2022 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$723.83M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.51 | 3.46%
|
Avg Daily Range (30 D): |
$0.23 | 3.52%
|
Avg Daily Range (90 D): |
$0.19 | 3.84%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.13M |
Avg Daily Volume (30 D): |
1.45M |
Avg Daily Volume (90 D): |
1.02M |
Trade Size |
Avg Trade Size (Sh.): |
95 |
Avg Trade Size (Sh.) (30 D): |
93 |
Avg Trade Size (Sh.) (90 D): |
97 |
Institutional Trades |
Total Inst.Trades: |
1,319 |
Avg Inst. Trade: |
$1.84M |
Avg Inst. Trade (30 D): |
$2.33M |
Avg Inst. Trade (90 D): |
$2.09M |
Avg Inst. Trade Volume: |
.11M |
Avg Inst. Trades (Per Day): |
2 |
Market Closing Trades |
Avg Closing Trade: |
$2.34M |
Avg Closing Trade (30 D): |
$3.31M |
Avg Closing Trade (90 D): |
$3.12M |
Avg Closing Volume: |
151.41K |
|
|
News |
Jul 14, 2025 @ 10:26 PM
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Inves...
Source: Bragar Eagel & Squire, P.C.
|
Jul 8, 2025 @ 1:00 AM
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Inves...
Source: Bragar Eagel & Squire, P.C.
|
Oct 18, 2024 @ 11:26 AM
Why Amylyx Pharmaceuticals Stock Was So Healthy Th...
Source: Eric Volkman
|
May 10, 2024 @ 6:01 PM
Breaking Down Amylyx Pharma: 9 Analysts Share Thei...
Source: Benzinga Insights
|
May 9, 2024 @ 12:15 PM
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Los...
Source: Zacks Equity Research
|
Financials |
|
TTM |
Q1 2025 |
Q4 2024 |
Basic EPS
|
$-3.1
|
$-.42
|
$-.54
|
Diluted EPS
|
$-3.1
|
$-.42
|
$-.54
|
Revenue
|
$ -1.27M
|
$ M
|
$ -.67M
|
Gross Profit
|
$
|
$
|
$ -.67M
|
Net Income / Loss
|
$ -218.86M
|
$ -35.91M
|
$ -37.55M
|
Operating Income / Loss
|
$ -230.4M
|
$ -37.8M
|
$ -40.65M
|
Cost of Revenue
|
$ .01M
|
$ M
|
$ M
|
Net Cash Flow
|
$ -110.06M
|
$ -17.62M
|
$ 5.56M
|
PE Ratio
|
|
|
|
|
|
|